Maureane Hoffman

About

Professor Maureane Hoffman is a Professor of Pathology and Assistant Professor of Integrative Immunobiology at Duke University. Her laboratory focuses on studying the mechanisms of hemostasis, contributing significantly to the field by developing a cell-based model of coagulation that offers a more physiologically relevant alternative to the traditional cascade model. This innovative approach has enhanced the understanding of how drugs can modulate hemostasis to prevent thrombosis, aiming to design improved therapeutic strategies. Additionally, her research explores the influence of coagulation products on inflammatory and immune responses, angiogenesis, and tissue repair, highlighting the complex interplay between coagulation and other biological processes.

Research topics

• Medicine
• Internal medicine
• Immunology
• Intensive care medicine
• Surgery
• Biochemistry
• Biology
• Cell biology
• Anesthesia
• Chemistry

Selected publications

• Trauma-induced coagulopathy

  Nature Reviews Disease Primers · 2021 · 760 citations

  PublisherOA PDFDOI

• Thrombin generation and implications for hemophilia therapies: A narrative review

  Research and Practice in Thrombosis and Haemostasis · 2023-01-01 · 41 citations

  reviewOpen access

  Thrombin plays an essential role in achieving and maintaining effective hemostasis and stable clot formation. In people with hemophilia, deficiency of procoagulant factor (F)VIII or FIX results in insufficient thrombin generation, leading to reduced clot stability and various bleeding manifestations. A correlation has been found between the bleeding phenotype of people with hemophilia and the extent of thrombin generation, with individuals with increased thrombin generation being protected from…

  PublisherDOI

• Ultrasoft platelet-like particles stop bleeding in rodent and porcine models of trauma

  Science Translational Medicine · 2024-04-10 · 38 citations

  articleOpen access

  Uncontrolled bleeding after trauma represents a substantial clinical problem. The current standard of care to treat bleeding after trauma is transfusion of blood products including platelets; however, donated platelets have a short shelf life, are in limited supply, and carry immunogenicity and contamination risks. Consequently, there is a critical need to develop hemostatic platelet alternatives. To this end, we developed synthetic platelet-like particles (PLPs), formulated by functionalizing h…

  PublisherOA PDFDOI

• Inhalation of an RNA aptamer that selectively binds extracellular histones protects from acute lung injury

  Molecular Therapy — Nucleic Acids · 2023-02-24 · 14 citations

  articleOpen access

  Acute lung injury (ALI) is a syndrome of acute inflammation, barrier disruption, and hypoxemic respiratory failure associated with high morbidity and mortality. Diverse conditions lead to ALI, including inhalation of toxic substances, aspiration of gastric contents, infection, and trauma. A shared mechanism of acute lung injury is cellular toxicity from damage-associated molecular patterns (DAMPs), including extracellular histones. We recently described the selection and efficacy of a histone-bi…

  PublisherOA PDFDOI

• Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors

  Nature Communications · 2021-11-25 · 12 citations

  articleOpen access

  Abstract Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a K i of 4.0 pM, 445-fold better than bivalirudin. Unexpectedly, despite their greater antithrombotic effect, variegin/ultravariegin dem…

  PublisherOA PDFDOI

Frequent coauthors

• Dougald M. Monroe

  University of North Carolina at Chapel Hill

  262 shared

• Harold R. Roberts

  Washington University in St. Louis

  131 shared

• Alisa S. Wolberg

  University of North Carolina at Chapel Hill

  95 shared

• Derrick L. Sauls

  Saint Augustine's University

  34 shared

• Ulla Hedner

  32 shared

• Geoffrey Allen

  Fulcrum Therapeutics (United States)

  27 shared

• Frank Church

  25 shared

• Angela Lenkowski

  Novo Nordisk (Denmark)

  25 shared

Education

• Residency Training AP/CP, Pathology

  Duke University Health System

  1985

• MD, PhD, Pharmacology/Toxicology

  University of Iowa

  1982

Similar researchers at Duke University

• Jiaoti Huangh-105
• Soman Ninan Abrahamh-99
• Rex Colle Bentleyh-80